2019 American Transplant Congress
Hepatoblastoma Tumors Requiring Liver Transplantation Manifest Dysregulated Ciliary, Autophagy and Cell Cycling Pathways in Systems Biology Analysis
*Purpose: Liver transplantation (LT) can cure locally invasive, unresectable and chemo-resistant hepatoblastoma (HBL), an embryonal liver tumor of infancy. Post-LT immunosuppression enhances recurrence-risk despite chemotherapy.*Methods:…2019 American Transplant Congress
The Effect of Lifestyle Intervention on Physical Functionality, Progress of Liver Disease and Mortality in Decompensated Cirrhosis Patients in a Community Model
Liver Institute PLLC, Tucson, AZ
*Purpose: The study was designed to look at relationships between diet and exercise interventions and liver disease prognosis in terms of survival and ability to…2019 American Transplant Congress
Targeted Antifungal Prophylaxis in Liver Transplant Recipients: Two Year, Retrospective Cohort Analysis
*Purpose: No consensus exists regarding systemic antifungal prophylaxis in liver transplant recipients (LTRs) in terms of optimal duration, choice of agent, or risk factors to…2019 American Transplant Congress
Evaluation of Liver Function and Biomarkers Predicts Tumor Progression in Treatment-Naïve Hepatocellular Carinoma Patients
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related deaths in the world with recurrence rates at 40%. Locoregional therapy (LRT) is standard…2019 American Transplant Congress
Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients
*Purpose: Compare incidence of post-transplant diabetes mellitus (PTDM) in hepatitis C virus (HCV) patients with and without viremia at the time of orthotopic liver transplantation…2019 American Transplant Congress
Ligation of the Proximal Splenic Vein to Keep Adequate Portal Flow in Patients with Large Splenorenal Shunts during Living Donor Liver Transplantation
*Purpose: Adequate graft portal venous flow is essential for the rapid regeneration of partial grafts during living donor liver transplantation (LDLT). Large splenorenal shunts (SRS)…2019 American Transplant Congress
Early Allograft Dysfunction in High Acuity Liver Transplant Recipients
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Organ recipient matching in Liver Transplantation (LT) has become ever-more challenging with the ongoing organ scarcity and increasing patient acuity. While the notion that…2019 American Transplant Congress
Living Donor vs. Deceased Donor Liver Transplantation for Pediatric Patients with Metabolic Liver Disease
Renji Hospital, Shanghai, China
*Purpose: Liver transplantation has been accepted as the appropriate treatment option for pediatric metabolic liver disease and the most common methods used are LDLT and…2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…2019 American Transplant Congress
Leukopenia at the Time of Liver Transplantation: Medication Tolerance and Clinical Outcomes
*Purpose: Leukopenia post-orthotopic liver transplant (OLT) is associated with an increased incidence of infection and mortality. Prior to OLT, leukopenia may suggest innate immunosuppression and…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 180
- Next Page »